AMENDMENTS

Amendments to the Specification:

On page 1, lines 6-7, please replace that paragraph with the following paragraph:

This application is a continuation of U.S. patent application serial no. 09/307,816 filed May 10, 1999, now U.S. Patent No. 6,306,393, which is a continuation-in-part of U.S. patent application serial no. 09/038,955 filed March 12, 1998, now U.S. Patent No. 6,183,744, which claims the benefit of Provisional Application No. 60/041,506 filed March 24, 1997.

Please delete the paragraph at page 27, line 30 through page 28, line 2 and replace therewith the following paragraph:

Suitable IL-2 formulations include PROLEUKIN® (IL-2 aldesleukin) (Chiron Corp./Cetus Oncology Corp.; Emeryville, Calif.) and TECELEUKIN® (Interleukin-2) (Hoffmann-La Roche, Inc.; Nutley, N.J.). ACTIMMUNE® (Interferon gamma-1b) (Genentech, Inc.; South San Francisco, Calif.) is a suitable INF-γ preparation.

Please delete the paragraph at page 19, lines 9-16 and replace therewith the following paragraph:

Before conjugation, the antibody is reduced by 50 mM 2-mercaptoethanol for 10 minutes at 4 °C. in 0.2 M Tris buffer (pH 8.7). The reduced antibody is separated from excess 2-mercaptoethanol with a Sephadex G-25 spin column, equilibrated in 50 mM sodium acetate buffered 0.9% saline (pH 5.3). The product is assayed for protein concentration by measuring its absorbance at 280 nm (and assuming that a 1 mg/ml antibody solution of 1.4) or by quantitation of ^{125}I-labeled antibody. Thiol groups are determined with ALDRITHIOL™ (2,2'-dipyridyl disulfide) following the change in absorbance at 343 nm and with cystein as standard.